NCT04729010

Brief Summary

This is a single-center, double-blind, placebo-controlled trial to see if acupuncture can safely and effectively manage anxiety in Parkinson's Disease. Eligible subjects will receive either real or sham acupuncture THREE times weekly for a total of SIX weeks.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for not_applicable parkinson-disease

Timeline
Completed

Started Oct 2021

Typical duration for not_applicable parkinson-disease

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 25, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 28, 2021

Completed
8 months until next milestone

Study Start

First participant enrolled

October 1, 2021

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2024

Completed
Last Updated

February 2, 2021

Status Verified

January 1, 2021

Enrollment Period

1.9 years

First QC Date

January 25, 2021

Last Update Submit

January 28, 2021

Conditions

Keywords

Acupuncture, Anxiety, Parkinson's Disease

Outcome Measures

Primary Outcomes (2)

  • Change in the Hamilton Anxiety Scale (HAM-A) between the treatment group.

    The primary outcome measure will be the change between the baseline visit and the SIX-week time point in the Hamilton Anxiety Scale (HAM-A) between the treatment group. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe.

    SIX weeks

  • Change in the Generalized Anxiety Disorder 7-Item (GAD-7) scale between the treatment group.

    The primary outcome measure will be the change between the baseline visit and the SIX-week time point in the Generalized Anxiety Disorder 7-Item (GAD-7) scale between the treatment group. Each item is scored on a scale of 0 (not at all) to 3 (Nearly Every Day), with a total score range of 0-56, where \<4 indicates Minimal Anxiety, 5-9 Mild Anxiety, 10-14 Moderate Anxiety, and 15-21 Severe Anxiety.

    SIX Weeks

Secondary Outcomes (1)

  • Change in the Unified Parkinson's Disease Rating Scale between the treatment group.

    THREE months

Study Arms (2)

Randomized Subjects receive a sham acupuncture.

SHAM COMPARATOR

Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.

Other: Acupuncture to treat anxiety in Parkinson disease

Randomized Subjects receive a real acupuncture.

ACTIVE COMPARATOR

Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.

Other: Acupuncture to treat anxiety in Parkinson disease

Interventions

Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.

Randomized Subjects receive a real acupuncture.Randomized Subjects receive a sham acupuncture.

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with Parkinson's Disease by authorized Neurologist.
  • Patients 40-75 years of age
  • Patients who have significant anxiety symptom
  • Patients must be on a stable medication regimen for the treatment of PD

You may not qualify if:

  • Patients who have had previous acupuncture within the past SIX months
  • Patients with dementia, depression, or sleep disorder
  • Patients who are currently taking medications known to affect anxiety

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Parkinson DiseaseAnxiety Disorders

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative DiseasesMental Disorders

Central Study Contacts

Yun Jin Kim, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 25, 2021

First Posted

January 28, 2021

Study Start

October 1, 2021

Primary Completion

September 1, 2023

Study Completion

May 1, 2024

Last Updated

February 2, 2021

Record last verified: 2021-01

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, CSR